Those of you that understand this awful disease will be glad to learn Roche (NASDAQOTH:RHHBY) has a drug on deck that could send all those rookies back to the minor leagues.
No two multiple sclerosis patients are the same, and despite the recent plethora of options, neurologists still face an awful dilemma. They must decide if a patient's disease is serious enough to warrant treatment with a drug that's highly effective, but potentially fatal.
Or, physicians could prescribe a wonderfully safe drug that might not stop their disease from progressing. Needless to say, it's not a decision taken lightly......
http://www.fool.com/investing/genera...-youve-ne.aspx